Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.47 |
| ▸ | ABL1 | P00519 | 6/20 | 0.38 |
| ▸ | BCR | P11274 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720717 | 0.92 | TRPV1 (0.56) | TRPV1ABL1BCRFAAH | |
| SCHEMBL4819487 | 0.91 | TRPV1 (0.55) | TRPV1ABL1BCRFAAH | |
| SCHEMBL4819481 | 0.88 | TRPV1 (0.43) | TRPV1ABL1BCRCYP1A2CYP3A4 | |
| SCHEMBL4715985 | 0.82 | MAPK10 (0.44) | TRPV1ABL1 | |
| SCHEMBL4716112 | 0.78 | MAPK10 (0.39) | TRPV1CYP1A2ALDH1A1HPGD | |
| SCHEMBL4718655 | 0.73 | TRPV1 (0.59) | TRPV1ABL1BCRFAAH | |
| SCHEMBL1013451 | 0.72 | TRPV1 (0.60) | TRPV1ABL1BCRCYP1A2CYP3A4 | |
| SCHEMBL5357407 | 0.71 | ABL1 (0.56) | TRPV1ABL1BCRCYP1A2CYP3A4 | |
| SCHEMBL1013757 | 0.70 | TRPV1 (0.78) | TRPV1ABL1BCRFAAH | |
| SCHEMBL4715897 | 0.70 | TRPV1 (0.44) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442701-B2 | Amino-heterocycles as VR-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2008-10-28 | — | — | US | disclosed |
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | OPRL1, CNR1, GPR6 | TRPV1 40/4885ABL1 3380/4885BCR 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.